Contrary to initial concerns, long-term safety data for thrombopoietin receptor agonists has allayed fears of malignant transformation and irreversible bone marrow fibrosis. The increased reticulin fibrosis observed is reversible upon drug discontinuation, offering significant reassurance for long-term prescribing.

Historical data on high splenectomy success rates in ITP is outdated. For modern patients who have already failed multiple lines of therapy (e.g., corticosteroids and a TPORA), the likelihood of a curative response from splenectomy falls to around 40-45%, making it a less appealing option.

The VEHIT2 trial protocol, combining yanalumab and eltrombopag shortly after steroid failure, represents a paradigm shift. It moves beyond sequential single-agent therapy to explore if early, potent intervention can fundamentally reduce the long-term severity and chronic nature of ITP.

Contrary to common assumptions, standard initial steroid therapy is ineffective for the vast majority of adult ITP patients. Approximately 80% progress to chronic disease, highlighting the urgent need for more effective first- and second-line therapies to alter the disease course.

The treatment paradigm for ITP is shifting towards early combination therapy. Recent clinical trials are investigating augmented first- and second-line regimens, such as combining dexamethasone with rituximab or romiplostim, to achieve more durable, treatment-free responses than monotherapy.

Concerns about bone marrow fibrosis with TPO receptor agonists have been resolved. The effect is a reversible increase in reticulin fibrosis, not the permanent collagen fibrosis seen in myelofibrosis. It resolves upon stopping the drug, so routine bone marrow biopsies for monitoring are unnecessary.

Patients with ITP who fail or are intolerant to one TPO receptor agonist (e.g., eltrombopag) should not be considered a class failure. Switching to another TPO agent is a viable strategy that can induce a response in nearly half of these cases, particularly for intolerance.

While not standard of care, TPO receptor agonists like romiplostim can be used in the third trimester of pregnancy to raise platelet counts above 75,000 for epidural anesthesia. This is considered a reasonable option after critical fetal development is complete, avoiding the need for pre-pregnancy splenectomy.

Eltrombopag is a potent iron chelator that can cause or worsen iron deficiency. In ITP patients with existing iron deficiency, alternative TPO receptor agonists like avatrombopag or romiplostim, which do not chelate iron, should be used instead.